Literature DB >> 18471548

Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.

Sharif B Missiha1, Mario Ostrowski, E Jenny Heathcote.   

Abstract

The hepatic complications of chronic hepatitis C (CHC) usually occur only after progression to cirrhosis has taken place. Progression to cirrhosis, however, is extremely variable and depends on a broad set of host and viral factors that modify the rate at which fibrosis develops in a given individual. Despite their inherent limitations, studies of the natural history of CHC have identified several nonmodifiable factors associated with disease progression. These include age at acquisition of infection, sex, and race. More recent reports suggest important roles for host genetic polymorphisms and viral factors. Of greater immediate relevance to patients and their clinicians are the potentially modifiable factors, which include excessive alcohol consumption; smoking (tobacco and marijuana); insulin resistance; and coinfection with hepatitis B virus, human immunodeficiency virus type 1, or schistosomiasis. Unfortunately, to date, there are no reliable predictive models that can accurately estimate the risk of CHC disease progression.

Entities:  

Mesh:

Year:  2008        PMID: 18471548     DOI: 10.1053/j.gastro.2008.02.069

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  58 in total

1.  IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.

Authors:  Vito Di Marco; Fabrizio Bronte; Vincenza Calvaruso; Marcello Capra; Zelia Borsellino; Aurelio Maggio; Maria Concetta Renda; Lorella Pitrolo; Maria Carmela Lo Pinto; Michele Rizzo; Flavia Fiorenza; Calogera Gerardi; Stefania Grimaudo; Antonietta Di Cristina; Massimo Levrero; Antonio Craxì
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

2.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

3.  Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C.

Authors:  Annarosa Cussigh; Edmondo Falleti; Carlo Fabris; Davide Bitetto; Sara Cmet; Elisabetta Fontanini; Sara Bignulin; Ezio Fornasiere; Elisa Fumolo; Rosalba Minisini; Mario Pirisi; Pierluigi Toniutto
Journal:  Immunogenetics       Date:  2010-11-12       Impact factor: 2.846

Review 4.  Hepatitis C in India.

Authors:  Ashis Mukhopadhyaya
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

Review 5.  From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence.

Authors:  Gayatri Ramakrishna; Archana Rastogi; Nirupama Trehanpati; Bijoya Sen; Ritu Khosla; Shiv K Sarin
Journal:  Liver Cancer       Date:  2013-08       Impact factor: 11.740

Review 6.  What is expected from the pathologist in the diagnosis of viral hepatitis?

Authors:  Helmut Denk
Journal:  Virchows Arch       Date:  2011-02-26       Impact factor: 4.064

7.  RNA triphosphatase DUSP11 enables exonuclease XRN-mediated restriction of hepatitis C virus.

Authors:  Rodney P Kincaid; Victor L Lam; Rachel P Chirayil; Glenn Randall; Christopher S Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-23       Impact factor: 11.205

8.  Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.

Authors:  Etienne Patin; Zoltán Kutalik; Julien Guergnon; Stéphanie Bibert; Bertrand Nalpas; Emmanuelle Jouanguy; Mona Munteanu; Laurence Bousquet; Laurent Argiro; Philippe Halfon; Anne Boland; Beat Müllhaupt; David Semela; Jean-François Dufour; Markus H Heim; Darius Moradpour; Andreas Cerny; Raffaele Malinverni; Hans Hirsch; Gladys Martinetti; Vijayaprakash Suppiah; Graeme Stewart; David R Booth; Jacob George; Jean-Laurent Casanova; Christian Bréchot; Charles M Rice; Andrew H Talal; Ira M Jacobson; Marc Bourlière; Ioannis Theodorou; Thierry Poynard; Francesco Negro; Stanislas Pol; Pierre-Yves Bochud; Laurent Abel
Journal:  Gastroenterology       Date:  2012-07-27       Impact factor: 22.682

Review 9.  Is liver biopsy still needed in children with chronic viral hepatitis?

Authors:  Maria Pokorska-Śpiewak; Barbara Kowalik-Mikołajewska; Małgorzata Aniszewska; Magdalena Pluta; Magdalena Marczyńska
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection.

Authors:  Matthew Hoare; William T H Gelson; Abhi Das; Jean M Fletcher; Susan E Davies; Martin D Curran; Sarah L Vowler; Mala K Maini; Arne N Akbar; Graeme J M Alexander
Journal:  J Hepatol       Date:  2010-04-22       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.